Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 9,560 Shares of Stock

Zymeworks Inc. (NYSE:ZYME) insider Paul Andrew Moore sold 9,560 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $216,725.20. Following the completion of the sale, the insider owned 48,497 shares of the company’s stock, valued at $1,099,426.99. This trade represents a 16.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Paul Andrew Moore also recently made the following trade(s):

• On Monday, January 5th, Paul Andrew Moore sold 20,110 shares of Zymeworks stock. The shares were sold at an average price of $25.10, for a total value of $504,761.00.

Zymeworks Stock Down 0.0%

Shares of Zymeworks stock opened at $23.16 on Tuesday. The stock’s fifty day moving average is $24.32 and its two-hundred day moving average is $18.42. The company has a market capitalization of $1.73 billion, a PE ratio of -15.44 and a beta of 1.30. Zymeworks Inc. has a 52 week low of $9.03 and a 52 week high of $28.49.

Zymeworks (NYSE:ZYME) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. The company had revenue of $27.61 million for the quarter, compared to the consensus estimate of $33.69 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm’s revenue was up 72.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.39) EPS. As a group, research analysts anticipate that Zymeworks Inc. will post -1.39 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ZYME shares. Truist Financial assumed coverage on shares of Zymeworks in a research note on Wednesday, December 17th. They set a “buy” rating and a $40.00 price objective on the stock. B. Riley reiterated a “buy” rating and set a $40.00 price objective (up previously from $30.00) on shares of Zymeworks in a report on Friday, November 21st. HC Wainwright lifted their target price on shares of Zymeworks from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. JMP Securities set a $32.00 price target on Zymeworks in a research report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Zymeworks from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Eleven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $32.82.

Institutional Trading of Zymeworks

Several institutional investors have recently modified their holdings of the stock. Optiver Holding B.V. purchased a new stake in Zymeworks during the 3rd quarter worth approximately $26,000. Quarry LP purchased a new position in shares of Zymeworks during the 3rd quarter worth $50,000. Tower Research Capital LLC TRC boosted its holdings in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after purchasing an additional 1,131 shares during the last quarter. CWM LLC lifted its holdings in Zymeworks by 272.8% in the second quarter. CWM LLC now owns 8,570 shares of the company’s stock valued at $108,000 after acquiring an additional 6,271 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Zymeworks by 157.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,307 shares of the company’s stock worth $129,000 after purchasing an additional 6,307 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with a focus on the discovery, development and commercialization of multifunctional biotherapeutics. Founded in 2003, the company applies proprietary protein engineering platforms to create novel antibody and protein-based therapies targeting oncology and other serious diseases. Zymeworks is publicly traded on the New York Stock Exchange under the symbol ZYME.

The company’s core technology platforms include Azymetric®, which enables the design of bispecific antibodies capable of engaging two distinct targets simultaneously, and the EFECT™ platform for fine-tuning antibody-drug conjugate properties.